| P2093 | author name string | Gervasio A Lamas | |
| | Vivian Fonseca | |
| | Denisse Diaz | |
| | Yamil W Aude | |
| P2860 | cites work | Lead-induced hypertension: possible role of endothelial factors | Q72247821 |
| | Lead acetate-induced contraction in rabbit mesenteric artery: interaction with calcium and protein kinase C | Q72266319 |
| | The relationship of cadmium in the air to cardiovascular disease death rates | Q72887141 |
| | Metabolism and removal of Ca45 in man | Q73143962 |
| | The in vivo dissolution of metastatic calcium; an approach to atherosclerosis | Q73707974 |
| | Clinical evaluation of chelation therapy: is there any wheat amidst the chaff? | Q73939540 |
| | Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid | Q74282172 |
| | Principles and recent developments in chelation treatment of metal intoxication | Q77367212 |
| | Hypertension induced in rats by small doses of cadmium | Q79413191 |
| | Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults | Q80284312 |
| | Heavy Metals, Cardiovascular Disease, and the Unexpected Benefits of Chelation Therapy | Q26747605 |
| | Metal pollutants and cardiovascular disease: mechanisms and consequences of exposure | Q27023569 |
| | Elevated Blood Lead Levels in Children Associated With the Flint Drinking Water Crisis: A Spatial Analysis of Risk and Public Health Response | Q27039007 |
| | Cadmium toxicity and treatment | Q28384540 |
| | Cadmium exposure and clinical cardiovascular disease: a systematic review | Q28392725 |
| | Cadmium exposure and incident cardiovascular disease | Q28392939 |
| | Chelation therapy for atherosclerotic cardiovascular disease | Q30880009 |
| | Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide | Q32069577 |
| | Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial | Q33792060 |
| | The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT) | Q33952145 |
| | Chelation therapy for ischemic heart disease: a randomized controlled trial | Q34110046 |
| | Blood and urine cadmium, blood pressure, and hypertension: a systematic review and meta-analysis | Q34407445 |
| | Blood lead levels and death from all causes, cardiovascular disease, and cancer: results from the NHANES III mortality study | Q35113268 |
| | Design of the Trial to Assess Chelation Therapy (TACT) | Q35627506 |
| | Kinetic analysis of lead metabolism in healthy humans | Q35902933 |
| | Cadmium levels in urine and mortality among U.S. adults | Q37112497 |
| | Lead exposure promotes translocation of protein kinase C activities in rat choroid plexus in vitro, but not in vivo | Q37183827 |
| | Cadmium body burden and increased blood pressure in middle-aged American Indians: the Strong Heart Study | Q37632997 |
| | Role of oxidative stress in development of complications in diabetes | Q37681089 |
| | Cadmium and cardiovascular diseases: cell biology, pathophysiology, and epidemiological relevance. | Q37705016 |
| | Unlocking the biology of RAGE in diabetic microvascular complications | Q38134924 |
| | Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. | Q40626983 |
| | RAGE: a novel cellular receptor for advanced glycation end products | Q41011414 |
| | Lead promotes hydroxyl radical generation and lipid peroxidation in cultured aortic endothelial cells | Q41737860 |
| | General aspects of cadmium: transport, uptake and metabolism by the kidney | Q42732602 |
| | EDTA chelation effects on urinary losses of cadmium, calcium, chromium, cobalt, copper, lead, magnesium, and zinc | Q43856686 |
| | Lead, cadmium, smoking, and increased risk of peripheral arterial disease | Q44927082 |
| | Lead-induced hypertension. II. Response to sequential infusions of L-arginine, superoxide dismutase, and nitroprusside | Q46466947 |
| | Lead-induced hypertension: interplay of nitric oxide and reactive oxygen species | Q46575082 |
| | Equine hepatic and renal metallothioneins. Purification, molecular weight, amino acid composition, and metal content. | Q47358524 |
| | Variation in cadmium accumulation potential and tissue distribution of cadmium in tobacco | Q47929251 |
| | Chelation therapy for intermittent claudication. A double-blind, randomized, controlled trial. | Q51131325 |
| | Cadmium is a novel and independent risk factor for early atherosclerosis mechanisms and in vivo relevance. | Q51630025 |
| | 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update of the Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelin | Q56040237 |
| | Low-Level Environmental Exposure to Lead Unmasked as Silent Killer | Q57085514 |
| | EDTA treatment of intermittent claudication--a double-blind, placebo-controlled study | Q68085865 |
| | The relationship of bone and blood lead to hypertension. The Normative Aging Study | Q71020894 |
| P433 | issue | 4 | |
| P304 | page(s) | 258-266 | |
| P577 | publication date | 2018-08-01 | |
| P1433 | published in | Current Opinion in Endocrinology, Diabetes and Obesity | Q15756285 |
| P1476 | title | Chelation therapy to prevent diabetes-associated cardiovascular events | |
| P478 | volume | 25 | |